[ The <font color="red">chemotherapy_1</font> <font color="red">of_1</font> <font color="red">advanced_3</font> <font color="red">breast_3</font> <font color="red">cancer_3</font> <font color="red">._3</font> A report on the <font color="red">first_1</font> <font color="red">600_3</font> <font color="red">cases_3</font> <font color="red">in_2</font> <font color="red">a_2</font> <font color="red">cooperative_2</font> <font color="red">programme_2</font> <font color="red">to_2</font> <font color="red">carry_2</font> <font color="red">out_2</font> <font color="red">a_2</font> <font color="red">systematic_2</font> <font color="red">study_2</font> <font color="red">(_1</font> <font color="red">1974_1</font> <font color="red">-_1</font> <font color="red">1977_1</font> <font color="red">)_1</font> ( author 's transl ) ] . 
<br>
<br> The authors explain the objectives and the structure of a programme evolved for the <font color="red">methodic_1</font> <font color="red">study_1</font> <font color="red">of_1</font> <font color="red">advanced_2</font> <font color="red">breast_2</font> <font color="red">cancers_2</font> which they have worked out and carried out in cooperation with the <font color="red">departments_3</font> <font color="red">of_3</font> <font color="red">medicine_3</font> <font color="red">in_3</font> <font color="red">eight_3</font> <font color="red">French_3</font> <font color="red">anticancer_3</font> <font color="red">centres_3</font> <font color="red">._3</font> They analyse the initial phases , which correspond to the three first years of work . They give the state of the results that have been obtained in <font color="red">603_5</font> <font color="red">patients_5</font> using three protocols for treatment . These consisted of the administration in <font color="red">interrupted_1</font> <font color="red">doses_1</font> <font color="red">of_1</font> <font color="red">chemotherapy_1</font> <font color="red">which_1</font> <font color="red">consisted_1</font> <font color="red">of_1</font> <font color="red">vincristine_1</font> <font color="red">associated_1</font> <font color="red">for_1</font> <font color="red">the_1</font> <font color="red">one_1</font> <font color="red">part_1</font> <font color="red">with_1</font> <font color="red">cyclophosphamide_1</font> <font color="red">and_1</font> <font color="red">5-fluoro_1</font> <font color="red">-_1</font> <font color="red">uracil_1</font> <font color="red">and_1</font> <font color="red">on_1</font> <font color="red">the_1</font> <font color="red">other_1</font> <font color="red">hand_1</font> <font color="red">with_1</font> <font color="red">doxorubicine_1</font> <font color="red">or_1</font> <font color="red">/_1</font> <font color="red">and_1</font> <font color="red">with_1</font> <font color="red">methotrexate_1</font> <font color="red">._1</font> From this study there emerged the value of combined therapy using doxorubicine as much because of the frequency with which results better than 50% were obtained ( in a randomised trial ) as by their quality , which was made clear in an important <font color="red">series_2</font> <font color="red">of_2</font> <font color="red">240_2</font> <font color="red">cases_2</font> <font color="red">._2</font> They point out the conditions required to initiate the place of such a scheme in all complex therapy which aims as much at palliation as at cure , and point out how important it is to be methodical in the application of chemotherapy in order to ensure its development as an anticancer therapy .